Payment overview · 2025
General Payments
$1,491.93
99 reported records · 22 companies
Healthcare provider profile · identity verified
Sanjaykumar B Shah, MD
Allopathic & Osteopathic Physicians|Family Medicine · BOSSIER CITY, LA · NPI 1740226505
Verified facts
What the public records show
CMS Open Payments records show Sanjaykumar B Shah, MD received $1,491.93 in general payments during 2025 across 99 reported records.
ABBVIE INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Voquezna.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Voquezna by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $352.22 | 23.6% | 28 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $183.94 | 12.3% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $134.55 | 9.0% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.34 | 8.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $79.75 | 5.3% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $74.85 | 5.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $72.42 | 4.8% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $58.42 | 3.9% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.70 | 3.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.84 | 2.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.23 | 2.7% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.37 | 2.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.71 | 2.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $34.82 | 2.3% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $31.71 | 2.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $28.24 | 1.9% | 1 | 2025 |
| Itamar Medical Inc | Unresolved — no canonical attribution shown | $22.60 | 1.5% | 1 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $22.40 | 1.5% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.39 | 1.5% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.52 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.51 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.40 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,491.93 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $174.16 | 12 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $110.89 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $108.46 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $90.51 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $87.55 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.04 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $74.85 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $74.85 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $73.05 | 5 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $72.87 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $72.42 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $66.25 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.99 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.79 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $58.42 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $49.51 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $48.42 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.84 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $40.23 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $35.87 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $34.82 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $31.71 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $27.07 | 2 | 2025 |
Source payment records
|
|||||
| WatchPATONE Normalized: watchpatone |
Device | Itamar Medical Inc | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $22.39 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.52 | 1 | 2025 |
Source payment records
|
|||||
| PREVYMIS Normalized: prevymis |
Drug | Merck Sharp & Dohme LLC | $15.51 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 107 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 508 | 338 |
| Amlodipine Besylate | Amlodipine Besylate | 425 | 136 |
| Atorvastatin Calcium | Atorvastatin Calcium | 365 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 332 | 105 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 327 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 82 |
| Gabapentin | Gabapentin | 261 | 78 |
| Losartan Potassium | Losartan Potassium | 199 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 196 | 63 |
| Lisinopril | Lisinopril | 188 | 56 |
| Metformin Hcl | Metformin Hcl | 184 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 59 |
| Furosemide | Furosemide | 159 | 54 |
| Omeprazole | Omeprazole | 152 | 44 |
| Cefprozil | Cefprozil | 151 | 126 |
| Lovastatin | Lovastatin | 149 | 45 |
| Carvedilol | Carvedilol | 132 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 40 |
| Simvastatin | Simvastatin | 126 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 39 |
| Nifedipine Er | Nifedipine | 123 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 120 | 102 |
| Metformin Hcl Er | Metformin Hcl | 119 | 39 |
| Azithromycin | Azithromycin | 117 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 39 |
| Glipizide Er | Glipizide | 109 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 35 |
| Ozempic | Semaglutide | 105 | 18 |
| Allopurinol | Allopurinol | 102 | 31 |
| Meloxicam | Meloxicam | 100 | 30 |
| Alendronate Sodium | Alendronate Sodium | 99 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 15 |
| Potassium Chloride | Potassium Chloride | 91 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 89 | 26 |
| Sertraline Hcl | Sertraline Hcl | 85 | 28 |
| Celecoxib | Celecoxib | 84 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 84 | 25 |
| Trazodone Hcl | Trazodone Hcl | 83 | 25 |
| Finasteride | Finasteride | 79 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 28 |
| Nebivolol Hcl | Nebivolol Hcl | 77 | 20 |
| Bupropion Xl | Bupropion Hcl | 74 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 17 |
| Donepezil Hcl | Donepezil Hcl | 68 | 26 |
| Ezetimibe | Ezetimibe | 68 | 22 |
| Montelukast Sodium | Montelukast Sodium | 68 | 23 |
| Januvia | Sitagliptin Phosphate | 67 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 19 |
| Pregabalin | Pregabalin | 63 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 62 | 17 |
| Jardiance | Empagliflozin | 61 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | 21 |
| Mounjaro | Tirzepatide | 59 | 14 |
| Cephalexin | Cephalexin | 57 | 49 |
| Eliquis | Apixaban | 56 | 19 |
| Levofloxacin | Levofloxacin | 55 | 43 |
| Buspirone Hcl | Buspirone Hcl | 54 | 17 |
| Trulicity | Dulaglutide | 53 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 48 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 48 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 44 |
| Mirtazapine | Mirtazapine | 44 | 15 |
| Clonidine Hcl | Clonidine Hcl | 43 | 14 |
| Temazepam | Temazepam | 42 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 41 | 19 |
| Methocarbamol | Methocarbamol | 40 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 15 |
| Tramadol Hcl | Tramadol Hcl | 40 | 26 |
| Atenolol | Atenolol | 38 | 16 |
| Glipizide | Glipizide | 38 | 12 |
| Primidone | Primidone | 37 | 12 |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 34 |
| Linzess | Linaclotide | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 16 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 30 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 11 |
| Fluconazole | Fluconazole | 29 | 21 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Colchicine | Colchicine | 28 | 17 |
| Bumetanide | Bumetanide | 27 | 11 |
| Colesevelam Hcl | Colesevelam Hcl | 27 | 15 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 20 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 16 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 16 |
| Diazepam | Diazepam | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 14 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 16 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Voquezna | Vonoprazan Fumarate | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Effer-K | Potassium Bicarbonate/Cit Ac | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,491.93 · 99 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, AREXVY, Auvelity, CREON, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Korlym, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVYMIS, PURIFIED CORTROPHIN GEL, Paradise Ultrasound Renal Denervation System, QULIPTA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VIBERZI, VOQUEZNA, VRAYLAR, Veozah, WatchPATONE, Wegovy, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error